Vera Therapeutics, Inc. (VERA) Financial Statements (2024 and earlier)

Company Profile

Business Address 8000 MARINA BOULEVARD, SUITE 120
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments114,71180,541
Cash and cash equivalents43,45979,674
Short-term investments71,252867
Prepaid expense1,2451,412
Deposits current assets  57
Other current assets823423
Other undisclosed current assets8,919104
Total current assets:125,69882,537
Noncurrent Assets
Operating lease, right-of-use asset5,173 
Property, plant and equipment51 
Long-term investments and receivables58867
Long-term investments58867
Regulated entity, other noncurrent assets  
Restricted cash and investments 293293
Other undisclosed noncurrent assets16251
Total noncurrent assets:5,7371,211
TOTAL ASSETS:131,43583,748
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22,9557,313
Accounts payable11,9911,385
Accrued liabilities10,9645,928
Restructuring reserve  377
Other undisclosed current liabilities2,645 
Total current liabilities:25,6007,690
Noncurrent Liabilities
Liabilities, other than long-term debt3,8311,257
Restructuring reserve  1,257
Operating lease, liability3,831 
Other undisclosed noncurrent liabilities25,0965,209
Total noncurrent liabilities:28,9276,466
Total liabilities:54,52714,156
Equity
Equity, attributable to parent, including:76,90869,592
Additional paid in capital290,216193,627
Accumulated other comprehensive loss(224) 
Accumulated deficit(213,112)(124,056)
Other undisclosed equity, attributable to parent2821
Total equity:76,90869,592
TOTAL LIABILITIES AND EQUITY:131,43583,748

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Revenues
(Other Income)
1,899 
Gross profit:1,899 
Operating expenses(90,903)(34,402)
Other undisclosed operating loss(1,899) 
Operating loss:(90,903)(34,402)
Nonoperating income1,8481,794
Investment income, nonoperating1,75015
Interest and debt expense(992)(20)
Loss from continuing operations before equity method investments, income taxes:(90,047)(32,628)
Other undisclosed income from continuing operations before income taxes99220
Loss from continuing operations before income taxes:(89,055)(32,608)
Income tax expense (benefit) (1)1
Other undisclosed loss from continuing operations  
Loss from continuing operations:(89,056)(32,607)
Loss before gain (loss) on sale of properties:(32,607)
Net loss:(89,056)(32,607)
Other undisclosed net income (loss) attributable to parent (2)
Net loss available to common stockholders, diluted:(89,056)(32,609)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(89,056)(32,607)
Other comprehensive loss(89,280) 
Other undisclosed comprehensive income  
Comprehensive loss, net of tax, attributable to parent:(178,336)(32,607)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: